Des Grade three Dermatitis acneiform All grades Dry skin All grades Discomfort All grades Grade three Pruritus All grades Anxiousness All grades Back discomfort All grades Grade three Chest pain All grades Pyrexia All grades Grade 3 Asthenia All grades Grade 3 Urinary tract infection All grades Insomnia All grades Grade three No. 41 two 0 35 3 0 24 two 21 2 16 1 16 three 13 13 ten 1 ten ten eight 3 eight 7 7 2 7 6 0 six 0 six 5 0 61.two three.0 0.0 52.2 four.5 0.0 35.8 3.0 31.three three.0 23.9 1.5 23.9 4.five 19.four 19.four 14.9 1.five 14.9 14.9 11.9 four.five 11.9 10.4 ten.4 3.0 ten.4 9.0 0.0 9.0 0.0 9.0 7.5 0.0 Onartuzumab Plus Erlotinib (n 69) No. 42 six 1 28 four 1 22 six 22 0 14 0 13 3 13 4 ten 0 10 8 4 1 4 six 7 1 2 ten 1 9 three 4 8 1 60.9 8.7 1.four 40.six five.8 1.four 31.9 eight.7 31.9 0.0 20.3 0.0 18.8 4.3 18.eight five.8 14.five 0.0 14.5 11.6 5.eight 1.4 five.eight eight.7 10.1 1.four 2.9 14.five 1.four 13.0 four.3 five.8 11.six 1.four MET Negative Placebo Plus Erlotinib (n 31) No. 18 1 0 17 1 0 11 1 ten 1 five 0 six 1 7 7 three 1 6 5 6 three 3 2 2 1 five two 0 3 0 four 2 0 58.1 3.2 0.0 54.8 3.two 0.0 35.5 three.two 32.3 three.two 16.1 0.0 19.four three.two 22.6 22.6 9.7 three.two 19.four 16.1 19.4 9.7 9.7 6.5 6.five three.2 16.1 six.five 0.0 9.7 0.0 12.9 6.five 0.0 Onartuzumab Plus Erlotinib (n 31) No. 18 two 0 8 1 0 six 2 9 0 four 0 4 1 4 two four 0 five 2 0 0 three 2 five 1 1 five 0 4 0 two 3 0 58.1 six.5 0.0 25.8 3.two 0.0 19.four six.five 29.0 0.0 12.9 0.0 12.9 three.2 12.9 six.five 12.9 0.0 16.1 6.5 0.0 0.0 9.7 6.5 16.1 three.2 3.two 16.1 0.0 12.9 0.0 six.5 9.7 0.0 MET Constructive Placebo Plus Erlotinib (n 31) No. 19 1 0 13 two 0 12 1 9 1 ten 0 8 two 6 five 6 0 three 5 1 0 five four 5 1 two three 0 two 0 2 three 0 61.3 3.2 0.0 41.9 six.five 0.0 38.7 three.2 29.0 3.two 32.3 0.0 25.8 6.five 19.4 16.1 19.four 0.0 9.7 16.1 three.2 0.0 16.1 12.9 16.1 3.2 six.five 9.7 0.0 six.5 0.0 6.5 9.7 0.0 Onartuzumab Plus Erlotinib (n 35) No. 22 four 1 18 3 1 16 four 13 0 10 0 eight 1 7 two 6 0 five 5 4 1 0 3 2 0 1 5 1 5 3 two 5 1 62.9 11.4 2.9 51.four eight.6 2.9 45.7 11.four 37.1 0.0 28.six 0.0 22.9 two.9 20.0 five.7 17.1 0.0 14.3 14.3 11.four two.9 0.0 8.six 5.7 0.0 two.9 14.three two.9 14.three 8.six 5.7 14.3 two.(continued on following page)www.jco.org2013 by American Society of Clinical OncologySpigel et alTable two. Most Generally Reported AEs (continued) ITT Placebo Plus Erlotinib (n 67) AE Peripheral edema All grades Grade three Pneumonia All grades Grade 3 Grade 5 No. 5 0 3 2 0 7.five 0.0 4.3-Cyclopropyl-1H-1,2,4-triazole web 5 three.Price of 620960-38-5 0 0.PMID:23543429 0 Onartuzumab Plus Erlotinib (n 69) No. 16 two five four 1 23.2 2.9 7.2 5.eight 1.four MET Negative Placebo Plus Erlotinib (n 31) No. 3 0 2 1 0 9.7 0.0 six.five 3.2 0.0 Onartuzumab Plus Erlotinib (n 31) No. 7 0 four 3 1 22.six 0.0 12.9 9.7 three.two MET Positive Placebo Plus Erlotinib (n 31) No. 2 0 1 1 0 6.5 0.0 3.2 three.two 0.0 Onartuzumab Plus Erlotinib (n 35) No. 8 2 1 1 0 22.9 five.7 two.9 2.9 0.NOTE. Table shows AEs occurring at frequency of ten , ordered by frequency in placebo plus erlotinib (ITT) group. Abbreviations: AE, adverse event; ITT, intent to treat. No grade four or five AEs. No grade 3 to five AEs. No grade 4 AEs.subgroups. The statistical significance in the therapy impact on OS was maintained within the MET-positive subgroup immediately after adjusting for sex in the Cox regression model (OS: HR, 0.35; P .0013). Similarly, benefits for most subgroups from the ITT population were consistent with the OS main evaluation (Fig 3B). PFS and OS analyses, removing identified EGFR mutation ositive individuals, were performed to address the imbalance in both METpositive and MET-negative populations. The overall interpretation of the benefits was unchanged (Fig four). Prognosis, assessed in sufferers assigned to placebo plus erlotinib, was worse in MET-positive versus MET-negative sufferers for both PFS (HR, 1.71; P .06) and OS (HR, 2.61; P .004; Appendix Fig A1, on the net only). For patient.